Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gallium ga-68 gozetotide
- Development stage
- Approved
- Lead developer
- Novartis
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
Gallium Ga‑68 gozetotide is a radiopharmaceutical diagnostic agent used for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer. It consists of a urea-based peptidomimetic ligand, Glu-NH‑CO‑NH-Lys(Ahx), conjugated to the chelator HBED‑CC and labeled with the positron-emitting radionuclide Gallium‑68. The drug binds specifically to PSMA, which is highly expressed on malignant prostate cancer cells, allowing for sensitive detection and localization of primary or recurrent prostate cancer as well as metastatic disease. Its main clinical indications include initial staging in high-risk or suspected metastatic cases prior to curative therapy, evaluation of suspected recurrence based on elevated PSA levels, and identification of patients eligible for PSMA-targeted therapies such as lutetium Lu 177 vipivotide tetraxetan[1][2][5][7].
- Brand names
- locametzilluccix
- Other names
- gallium (68ga) gozetotideglu-nh-co-nh-lys(ahx)-hbed-cc
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on gallium ga-68 gozetotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gallium ga-68 gozetotide.